First, early response to LNP-CTNNB1 treatment includes cessation of tumor cell proliferation and concomitant metabolic zonal reprogramming with zone 3 tumor cells converting to zone 1/2 hepatocytes. This evidence concerns the gene CTNNB1 and neoplasm.